{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:11:51Z","timestamp":1783977111060,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07046-5","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:33:31Z","timestamp":1778294011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["WT1 mRNA in peripheral blood enables early prognostic stratification in AML patients receiving venetoclax and azacitidine therapy"],"prefix":"10.1007","volume":"105","author":[{"given":"Hiroyuki","family":"Sugiura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Urata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"7046_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Illes A, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"7046_CR2","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA (2019) Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv 3:2911\u20132919. https:\/\/doi.org\/10.1182\/bloodadvances.2019000243","journal-title":"Blood Adv"},{"key":"7046_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93:401\u2013407. https:\/\/doi.org\/10.1002\/ajh.25000","journal-title":"Am J Hematol"},{"key":"7046_CR4","doi-asserted-by":"publisher","first-page":"107407","DOI":"10.1016\/j.leukres.2023.107407","volume":"135","author":"A Ravindra","year":"2023","unstructured":"Ravindra A, Acharya L, Loeffler B, Mott S, Sutamtewagul G, Dhakal P (2023) Venetoclax-based therapy in treatment-naive and relapsed\/refractory acute myeloid leukemia. Leuk Res 135:107407. https:\/\/doi.org\/10.1016\/j.leukres.2023.107407","journal-title":"Leuk Res"},{"key":"7046_CR5","doi-asserted-by":"publisher","unstructured":"Labrador J, Saiz-Rodriguez M, de Miguel D, de Laiglesia A, Rodriguez-Medina C, Vidriales MB, Perez-Encinas M, Sanchez-Sanchez MJ, Cuello R, Roldan-Perez A, Vives S, Benzo-Callejo G, Colorado M, Garcia-Fortes M, Sayas MJ, Olivier C, Recio I, Conde-Royo D, Bienert-Garcia A, Vahi M, Munoz-Garcia C, Seri-Merino C, Tormo M, Vall-Llovera F, Foncillas MA, Martinez-Cuadron D, Sanz MA, Montesinos P (2022) Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14071734","DOI":"10.3390\/cancers14071734"},{"key":"7046_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Dohner H (2022) Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol 40:855\u2013865. https:\/\/doi.org\/10.1200\/JCO.21.01546","journal-title":"J Clin Oncol"},{"key":"7046_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(90)90601-a","volume":"60","author":"KM Call","year":"1990","unstructured":"Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH et al (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms\u2019 tumor locus. Cell 60:509\u2013520. https:\/\/doi.org\/10.1016\/0092-8674(90)90601-a","journal-title":"Cell"},{"key":"7046_CR8","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/343774a0","volume":"343","author":"M Gessler","year":"1990","unstructured":"Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA (1990) Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343:774\u2013778. https:\/\/doi.org\/10.1038\/343774a0","journal-title":"Nature"},{"key":"7046_CR9","first-page":"1747s","volume":"59","author":"R Davies","year":"1999","unstructured":"Davies R, Moore A, Schedl A, Bratt E, Miyahawa K, Ladomery M, Miles C, Menke A, van Heyningen V, Hastie N (1999) Multiple roles for the Wilms\u2019 tumor suppressor, WT1. Cancer Res 59:1747s\u20131750 s; discussion 1751s","journal-title":"Cancer Res"},{"key":"7046_CR10","doi-asserted-by":"publisher","first-page":"890871","DOI":"10.3389\/fonc.2022.890871","volume":"12","author":"M Bernardi","year":"2022","unstructured":"Bernardi M, Ferrara F, Carrabba MG, Mastaglio S, Lorentino F, Vago L, Ciceri F (2022) MRD in Venetoclax-Based Treatment for AML: Does it Really Matter? Front Oncol 12:890871. https:\/\/doi.org\/10.3389\/fonc.2022.890871","journal-title":"Front Oncol"},{"key":"7046_CR11","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","volume":"5","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F (2021) Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5:1876\u20131883. https:\/\/doi.org\/10.1182\/bloodadvances.2020003717","journal-title":"Blood Adv"},{"key":"7046_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10147-024-02480-9","volume":"29","author":"H Sato","year":"2024","unstructured":"Sato H, Kobayashi T, Kameoka Y, Teshima K, Watanabe A, Yamada M, Yamashita T, Noguchi S, Michisita Y, Fujishima N, Kuroki J, Takahashi N (2024) Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy. Int J Clin Oncol 29:481\u2013492. https:\/\/doi.org\/10.1007\/s10147-024-02480-9","journal-title":"Int J Clin Oncol"},{"key":"7046_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"7046_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12185-015-1882-1","volume":"103","author":"K Kitamura","year":"2016","unstructured":"Kitamura K, Nishiyama T, Ishiyama K, Miyawaki S, Miyazaki K, Suzuki K, Masaie H, Okada M, Ogawa H, Imai K, Kiyoi H, Naoe T, Yokoyama Y, Chiba S, Hata T, Miyazaki Y, Hatta Y, Takeuchi J, Nannya Y, Kurokawa M, Ueda Y, Koga D, Sugiyama H, Takaku F (2016) Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood. Int J Hematol 103:53\u201362. https:\/\/doi.org\/10.1007\/s12185-015-1882-1","journal-title":"Int J Hematol"},{"key":"7046_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/blood.2023021579","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Tiong IS, O\u2019Nions J, Dennis M, Mokretar K, Ivey A, Austin M, Latif AL, Amer M, Chan WY, Crawley C, Crolla F, Cross J, Dang R, Elliot J, Fong CY, Galli S, Gallipoli P, Hogan F, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Loo S, Marshall S, Mehta P, Murthy V, Nagumantry S, Pillai S, Potter N, Sellar R, Taylor T, Zhao R, Russell NH, Wei AH, Dillon R (2024) Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. Blood 143:336\u2013341. https:\/\/doi.org\/10.1182\/blood.2023021579","journal-title":"Blood"},{"key":"7046_CR16","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1182\/bloodadvances.2021004322","volume":"5","author":"J Lambert","year":"2021","unstructured":"Lambert J, Lambert J, Thomas X, Marceau-Renaut A, Micol JB, Renneville A, Clappier E, Hayette S, Recher C, Raffoux E, Pigneux A, Berthon C, Terre C, Celli-Lebras K, Castaigne S, Boissel N, Rousselot P, Preudhomme C, Dombret H, Duployez N (2021) Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Adv 5:5258\u20135268. https:\/\/doi.org\/10.1182\/bloodadvances.2021004322","journal-title":"Blood Adv"},{"key":"7046_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12185-022-03290-3","volume":"115","author":"W Kitamura","year":"2022","unstructured":"Kitamura W, Fujii N, Nawa Y, Fujishita K, Sugiura H, Yoshioka T, Fujiwara Y, Usui Y, Fujii K, Fujiwara H, Asada N, Nishimori H, Matsuoka KI, Maeda Y (2022) Possible prognostic impact of WT1 mRNA expression at day\u2009+\u200930 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group. Int J Hematol 115:515\u2013524. https:\/\/doi.org\/10.1007\/s12185-022-03290-3","journal-title":"Int J Hematol"},{"key":"7046_CR18","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.3109\/10428194.2010.507829","volume":"51","author":"S Miyawaki","year":"2010","unstructured":"Miyawaki S, Hatsumi N, Tamaki T, Naoe T, Ozawa K, Kitamura K, Karasuno T, Mitani K, Kodera Y, Yamagami T, Koga D (2010) Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma 51:1855\u20131861. https:\/\/doi.org\/10.3109\/10428194.2010.507829","journal-title":"Leuk Lymphoma"},{"key":"7046_CR19","doi-asserted-by":"publisher","first-page":"E416","DOI":"10.1002\/ajh.26692","volume":"97","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, Stevens D, Kantarjian H, Traina F, Venditti A, Mayer J, Montez M, Jin H, Duan Y, Brackman D, Zha J, Potluri J, Werner M, Jonas BA (2022) Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol 97:E416\u2013E419. https:\/\/doi.org\/10.1002\/ajh.26692","journal-title":"Am J Hematol"},{"key":"7046_CR20","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","volume":"27","author":"D Cilloni","year":"2009","unstructured":"Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, Gottardi E, Fava M, Schnittger S, Weiss T, Izzo B, Nomdedeu J, van der Heijden A, van der Reijden BA, Jansen JH, van der Velden VH, Ommen H, Preudhomme C, Saglio G, Grimwade D (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 27:5195\u20135201. https:\/\/doi.org\/10.1200\/JCO.2009.22.4865","journal-title":"J Clin Oncol"},{"key":"7046_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123306","author":"D Lazzarotto","year":"2022","unstructured":"Lazzarotto D, Candoni A (2022) The Role of Wilms\u2019 Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia. J Clin Med 11. https:\/\/doi.org\/10.3390\/jcm11123306","journal-title":"J Clin Med 11"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07046-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07046-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07046-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:02:23Z","timestamp":1783976543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07046-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7046"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07046-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Okayama University Hospital (approved No. 2208-012; June 24, 2022). The requirement for written informed consent was waived due to the retrospective nature of the study, and an opt-out option was provided via the institutional website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Competing interests: KS has received research funding from ONO, BeiGene, AbbVie, Sanofi, Bristol Myers Squibb, GlaxoSmithKline, Chugai, Otsuka, Janssen, Novartis, Pfizer, Kyowa Kirin, Mitsubishi Tanabe, Incyte, and received honoraria from MS, Janssen, Sanofi, and Pfizer. YH has received honoraria from Chugai Pharmaceutical CO., Ltd and Sanofi K.K. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"309"}}